Subscribe
e.g. organoids

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Aggressive B-Cell Lymphomas in the CART Era

Scientists selected patients with the following characteristics: CART or allogeneic hematopoietic cell transplantation (alloHCT) performed between 2016 and 2021; ≥18 years old; aggressive B-cell lymphomas diagnosis; ≥2 lines of therapy; and either anti-CD19 CART or alloHCT as therapy at relapse.
[Bone Marrow Transplantation]
AbstractGraphical Abstract
Published In
NewslettersCell Therapy NewsHematopoiesis News
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News

RB1-Deficient Prostate Tumor Growth and Metastasis Are Vulnerable to Ferroptosis Induction via the E2F/ACSL4 Axis

[Journal Of Clinical Investigation] Researchers showed that RB1-loss/E2F activation sensitized cancer cells to ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, by upregulating expression of ACSL4 and enriching ACSL4-dependent arachidonic acid-containing phospholipids, which are key components of ferroptosis execution.
NewslettersProstate Cell News
Read more

Expression and Therapeutic Targeting of Trop-2 in Treatment Resistant Prostate Cancer

[Clinical Cancer Research] Scientists observed that Trop-2 can serve as a cell surface target for isolating circulating tumor cells, which may serve as a predictive biomarker for antibody drug conjugates.
NewslettersProstate Cell News
Read more

CD46 Targeted 212Pb Alpha Particle Radioimmunotherapy for Prostate Cancer Treatment

[Journal Of Experimental & Clinical Cancer Research] Investigators reported the development of a novel CD46-targeted alpha therapy based on the internalizing human monoclonal antibody, YS5.
NewslettersProstate Cell News
Read more
Brought to you by